Multimodality Treatment including Surgery Related to the Type of N2 Involvement in Locally Advanced Non-Small Cell Lung Cancer
For patients with locally advanced non-small cell lung cancer (NSCLC) or positive N1 nodes, multimodality treatment is indicated. However, the optimal management of patients presenting with ipsilateral positive mediastinal nodes (N2 disease) has not been determined yet. Different treatment regimens...
Gespeichert in:
| Veröffentlicht in: | Cancers 2022-03, Vol.14 (7), p.1656 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 7 |
| container_start_page | 1656 |
| container_title | Cancers |
| container_volume | 14 |
| creator | Allaeys, Toon Berzenji, Lawek Lauwers, Patrick Yogeswaran, Suresh Krishan Hendriks, Jeroen M H Billiet, Charlotte De Bondt, Charlotte Van Schil, Paul E |
| description | For patients with locally advanced non-small cell lung cancer (NSCLC) or positive N1 nodes, multimodality treatment is indicated. However, the optimal management of patients presenting with ipsilateral positive mediastinal nodes (N2 disease) has not been determined yet. Different treatment regimens consisting of chemotherapy, radiation therapy, and surgery have been proposed and implemented previously. In more recent years, immunotherapy and targeted therapies have been added as therapeutic options. The role of surgery is currently redefined. Recent studies have shown that surgical resection after induction immunotherapy or targeted therapy is feasible and yields good short-term results. In this review, we summarize the latest data on multimodality treatment options for stage IIIA-N2 locally advanced NSCLC, depending on the extent of nodal involvement. |
| doi_str_mv | 10.3390/cancers14071656 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8997106</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2649000869</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-3767cbff054aba79d493bea55a27e8402d792d35e6b05c06cae66b2f60c4b4093</originalsourceid><addsrcrecordid>eNpdkc9rHCEcxaU0NCHJubci9NLLNI46znophKU_AtsEku1ZHP3OZoKjW3UW5tK_vW6yDWk8qOj7Pj6Ph9D7mnxmTJILo72BmGpO2lo04g06oaSllRCSv31xP0bnKT2QshirW9G-Q8es4URwujhBf35OLg9jsNoNecbrCDqP4DMevHGTHfwG301xA3HGt-B0BotzwPke8HreAg49vqb4yu-C28FhDq-C0c7N-NLu9oQWXwdf3Y3lDS-hbKupuC4f4c_QUa9dgvPDeYp-ffu6Xv6oVjffr5aXq8pwWueKFWzT9T1puO50Ky2XrAPdNJq2sOCE2lZSyxoQHWkMEUaDEB3tBTG840SyU_TlyXc7dSNYU0ijdmobh1HHWQU9qP9__HCvNmGnFlK2NRHF4NPBIIbfE6SsxiGZkkZ7CFNSVHDZSEbbukg_vpI-hCn6Eu9RVXpYiD3RxZPKxJBShP4ZpiZqX696VW-Z-PAyw7P-X5nsL5hso1M</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2649000869</pqid></control><display><type>article</type><title>Multimodality Treatment including Surgery Related to the Type of N2 Involvement in Locally Advanced Non-Small Cell Lung Cancer</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><creator>Allaeys, Toon ; Berzenji, Lawek ; Lauwers, Patrick ; Yogeswaran, Suresh Krishan ; Hendriks, Jeroen M H ; Billiet, Charlotte ; De Bondt, Charlotte ; Van Schil, Paul E</creator><creatorcontrib>Allaeys, Toon ; Berzenji, Lawek ; Lauwers, Patrick ; Yogeswaran, Suresh Krishan ; Hendriks, Jeroen M H ; Billiet, Charlotte ; De Bondt, Charlotte ; Van Schil, Paul E</creatorcontrib><description>For patients with locally advanced non-small cell lung cancer (NSCLC) or positive N1 nodes, multimodality treatment is indicated. However, the optimal management of patients presenting with ipsilateral positive mediastinal nodes (N2 disease) has not been determined yet. Different treatment regimens consisting of chemotherapy, radiation therapy, and surgery have been proposed and implemented previously. In more recent years, immunotherapy and targeted therapies have been added as therapeutic options. The role of surgery is currently redefined. Recent studies have shown that surgical resection after induction immunotherapy or targeted therapy is feasible and yields good short-term results. In this review, we summarize the latest data on multimodality treatment options for stage IIIA-N2 locally advanced NSCLC, depending on the extent of nodal involvement.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers14071656</identifier><identifier>PMID: 35406428</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Algorithms ; Cancer therapies ; Chemotherapy ; Clinical medicine ; Immunotherapy ; Lung cancer ; Lymphatic system ; Medical prognosis ; Metastasis ; Multidisciplinary teams ; Nodes ; Non-small cell lung carcinoma ; Patients ; Radiation therapy ; Review ; Small cell lung carcinoma ; Surgery</subject><ispartof>Cancers, 2022-03, Vol.14 (7), p.1656</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-3767cbff054aba79d493bea55a27e8402d792d35e6b05c06cae66b2f60c4b4093</citedby><cites>FETCH-LOGICAL-c421t-3767cbff054aba79d493bea55a27e8402d792d35e6b05c06cae66b2f60c4b4093</cites><orcidid>0000-0002-1962-8821 ; 0000-0001-9145-3643 ; 0000-0002-0530-5407</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997106/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997106/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35406428$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Allaeys, Toon</creatorcontrib><creatorcontrib>Berzenji, Lawek</creatorcontrib><creatorcontrib>Lauwers, Patrick</creatorcontrib><creatorcontrib>Yogeswaran, Suresh Krishan</creatorcontrib><creatorcontrib>Hendriks, Jeroen M H</creatorcontrib><creatorcontrib>Billiet, Charlotte</creatorcontrib><creatorcontrib>De Bondt, Charlotte</creatorcontrib><creatorcontrib>Van Schil, Paul E</creatorcontrib><title>Multimodality Treatment including Surgery Related to the Type of N2 Involvement in Locally Advanced Non-Small Cell Lung Cancer</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>For patients with locally advanced non-small cell lung cancer (NSCLC) or positive N1 nodes, multimodality treatment is indicated. However, the optimal management of patients presenting with ipsilateral positive mediastinal nodes (N2 disease) has not been determined yet. Different treatment regimens consisting of chemotherapy, radiation therapy, and surgery have been proposed and implemented previously. In more recent years, immunotherapy and targeted therapies have been added as therapeutic options. The role of surgery is currently redefined. Recent studies have shown that surgical resection after induction immunotherapy or targeted therapy is feasible and yields good short-term results. In this review, we summarize the latest data on multimodality treatment options for stage IIIA-N2 locally advanced NSCLC, depending on the extent of nodal involvement.</description><subject>Algorithms</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Clinical medicine</subject><subject>Immunotherapy</subject><subject>Lung cancer</subject><subject>Lymphatic system</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Multidisciplinary teams</subject><subject>Nodes</subject><subject>Non-small cell lung carcinoma</subject><subject>Patients</subject><subject>Radiation therapy</subject><subject>Review</subject><subject>Small cell lung carcinoma</subject><subject>Surgery</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkc9rHCEcxaU0NCHJubci9NLLNI46znophKU_AtsEku1ZHP3OZoKjW3UW5tK_vW6yDWk8qOj7Pj6Ph9D7mnxmTJILo72BmGpO2lo04g06oaSllRCSv31xP0bnKT2QshirW9G-Q8es4URwujhBf35OLg9jsNoNecbrCDqP4DMevHGTHfwG301xA3HGt-B0BotzwPke8HreAg49vqb4yu-C28FhDq-C0c7N-NLu9oQWXwdf3Y3lDS-hbKupuC4f4c_QUa9dgvPDeYp-ffu6Xv6oVjffr5aXq8pwWueKFWzT9T1puO50Ky2XrAPdNJq2sOCE2lZSyxoQHWkMEUaDEB3tBTG840SyU_TlyXc7dSNYU0ijdmobh1HHWQU9qP9__HCvNmGnFlK2NRHF4NPBIIbfE6SsxiGZkkZ7CFNSVHDZSEbbukg_vpI-hCn6Eu9RVXpYiD3RxZPKxJBShP4ZpiZqX696VW-Z-PAyw7P-X5nsL5hso1M</recordid><startdate>20220325</startdate><enddate>20220325</enddate><creator>Allaeys, Toon</creator><creator>Berzenji, Lawek</creator><creator>Lauwers, Patrick</creator><creator>Yogeswaran, Suresh Krishan</creator><creator>Hendriks, Jeroen M H</creator><creator>Billiet, Charlotte</creator><creator>De Bondt, Charlotte</creator><creator>Van Schil, Paul E</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1962-8821</orcidid><orcidid>https://orcid.org/0000-0001-9145-3643</orcidid><orcidid>https://orcid.org/0000-0002-0530-5407</orcidid></search><sort><creationdate>20220325</creationdate><title>Multimodality Treatment including Surgery Related to the Type of N2 Involvement in Locally Advanced Non-Small Cell Lung Cancer</title><author>Allaeys, Toon ; Berzenji, Lawek ; Lauwers, Patrick ; Yogeswaran, Suresh Krishan ; Hendriks, Jeroen M H ; Billiet, Charlotte ; De Bondt, Charlotte ; Van Schil, Paul E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-3767cbff054aba79d493bea55a27e8402d792d35e6b05c06cae66b2f60c4b4093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Algorithms</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Clinical medicine</topic><topic>Immunotherapy</topic><topic>Lung cancer</topic><topic>Lymphatic system</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Multidisciplinary teams</topic><topic>Nodes</topic><topic>Non-small cell lung carcinoma</topic><topic>Patients</topic><topic>Radiation therapy</topic><topic>Review</topic><topic>Small cell lung carcinoma</topic><topic>Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Allaeys, Toon</creatorcontrib><creatorcontrib>Berzenji, Lawek</creatorcontrib><creatorcontrib>Lauwers, Patrick</creatorcontrib><creatorcontrib>Yogeswaran, Suresh Krishan</creatorcontrib><creatorcontrib>Hendriks, Jeroen M H</creatorcontrib><creatorcontrib>Billiet, Charlotte</creatorcontrib><creatorcontrib>De Bondt, Charlotte</creatorcontrib><creatorcontrib>Van Schil, Paul E</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Allaeys, Toon</au><au>Berzenji, Lawek</au><au>Lauwers, Patrick</au><au>Yogeswaran, Suresh Krishan</au><au>Hendriks, Jeroen M H</au><au>Billiet, Charlotte</au><au>De Bondt, Charlotte</au><au>Van Schil, Paul E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Multimodality Treatment including Surgery Related to the Type of N2 Involvement in Locally Advanced Non-Small Cell Lung Cancer</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2022-03-25</date><risdate>2022</risdate><volume>14</volume><issue>7</issue><spage>1656</spage><pages>1656-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>For patients with locally advanced non-small cell lung cancer (NSCLC) or positive N1 nodes, multimodality treatment is indicated. However, the optimal management of patients presenting with ipsilateral positive mediastinal nodes (N2 disease) has not been determined yet. Different treatment regimens consisting of chemotherapy, radiation therapy, and surgery have been proposed and implemented previously. In more recent years, immunotherapy and targeted therapies have been added as therapeutic options. The role of surgery is currently redefined. Recent studies have shown that surgical resection after induction immunotherapy or targeted therapy is feasible and yields good short-term results. In this review, we summarize the latest data on multimodality treatment options for stage IIIA-N2 locally advanced NSCLC, depending on the extent of nodal involvement.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>35406428</pmid><doi>10.3390/cancers14071656</doi><orcidid>https://orcid.org/0000-0002-1962-8821</orcidid><orcidid>https://orcid.org/0000-0001-9145-3643</orcidid><orcidid>https://orcid.org/0000-0002-0530-5407</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2022-03, Vol.14 (7), p.1656 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8997106 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central |
| subjects | Algorithms Cancer therapies Chemotherapy Clinical medicine Immunotherapy Lung cancer Lymphatic system Medical prognosis Metastasis Multidisciplinary teams Nodes Non-small cell lung carcinoma Patients Radiation therapy Review Small cell lung carcinoma Surgery |
| title | Multimodality Treatment including Surgery Related to the Type of N2 Involvement in Locally Advanced Non-Small Cell Lung Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T12%3A43%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Multimodality%20Treatment%20including%20Surgery%20Related%20to%20the%20Type%20of%20N2%20Involvement%20in%20Locally%20Advanced%20Non-Small%20Cell%20Lung%20Cancer&rft.jtitle=Cancers&rft.au=Allaeys,%20Toon&rft.date=2022-03-25&rft.volume=14&rft.issue=7&rft.spage=1656&rft.pages=1656-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers14071656&rft_dat=%3Cproquest_pubme%3E2649000869%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2649000869&rft_id=info:pmid/35406428&rfr_iscdi=true |